

Product Information

MISSION® shRNA Mouse Gene Family Sets, DNA Format

Catalog Numbers **SM0121**, **SM0421**, and **SM2021**

Storage Temperature –20 °C

TECHNICAL BULLETIN

Product Description

Small interfering RNAs (siRNAs) generated from short hairpin RNAs (shRNAs) are a powerful way to mediate gene specific RNA interference (RNAi) for extended periods of time in mammalian cells. The MISSION® product line is a viral-vector-based RNAi library against annotated mouse and human genes. MISSION shRNAs are expressed intracellularly after transduction with amphotropic lentivirus particles, allowing screening in a wide range of mammalian cell lines. In these cell lines, MISSION shRNA clones permit rapid, cost efficient loss-of-function and genetic interaction screens. These murine gene family sets were designed specifically for the most common mammalian model organism, the mouse. A collection of reviews that highlight the importance of each gene family set is included.

The MISSION shRNA Gene Family Sets contain shRNA clones that allow for high throughput loss-of-function and genetic interaction screens. Each MISSION shRNA clone is constructed within the lentivirus plasmid vector pLKO.1-puro.¹ The pLKO.1-puro vector contains the ampicillin and puromycin antibiotic resistance genes for selection of inserts in bacterial or mammalian cells, respectively. The set consists of sequence-verified shRNA lentiviral plasmid DNA. Each target set consists of 3 or more constructs that have been designed against each target gene using a proprietary algorithm. Therefore, a range of gene silencing efficiencies, with at least one construct from each gene set being >70%, can be expected when using these clones. This allows one to examine the effect of loss of gene function over a large series of gene knockdown efficiencies. Each shRNA construct has been cloned and sequence verified to ensure a match to the target gene.

RNAi knockdown be achieved either with the plasmid DNA or the MISSION lentiviral delivery system. Target cell lines may be transfected with the purified plasmid for transient or stable gene silencing (puromycin selection).

In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK 293T) by co-transfection with compatible packaging plasmids.^{2,3} Unlike murine-based MMLV or MSCV retroviral systems, lentiviral-based particles permit efficient infection and genomic integration of the specific shRNA construct into differentiated and non-dividing cells, such as neurons and dendritic cells, overcoming low transfection and integration difficulties when using these cell lines.

Please see the **Mouse Cell Type Table** for cell types that have been successfully infected by pLKO.1-puro based shRNA constructs.

Components

The individual constructs are provided as 40 µL of frozen stocks containing an average of 2 µg of plasmid DNA in Tris-EDTA (TE) buffer with amounts of DNA ranging from 400 ng to 4 µg per well. Sets are provided in 96-well plates with a one dimensional barcode label on each plate and a CD containing plate map positions.

The hairpin sequence and other unique clone information may be obtained by searching the MISSION search database at www.sigma.com/yfg using: RefSeq accession numbers, e.g., NM_027088, unique clone identification numbers e.g., NM_027088.1-989s1c1, or TRC numbers, e.g., TRCN0000030720

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability


All components are stable for at least one year after receipt when stored at –20 °C.

Catalog Number	Gene Family Set	Gene Count *	Clone Count *	Average Number Clones/Gene *
SM0121	Kinases	618	3916	6.3
SM0421	Phosphatases	290	1734	6.0
SM2021	Tyrosine Kinases	133	850	6.4

*The MISSION production and bio-informatics team constantly reviews and quality controls clones available for a gene family set. These numbers are very close to the actual number that will be shipped, but each researcher will receive a final plate map indicating the location and exact TRCN clone numbers.

Features of Lentiviral Plasmid Vector pLKO.1-puro

Name	Description
U6	U6 Promoter
cppt	Central polypurine tract
hPGK	Human phosphoglycerate kinase eukaryotic promoter
puroR	Puromycin resistance gene for mammalian selection
SIN/3' LTR	3' self inactivating long terminal repeat
f1 ori	f1 origin of replication
ampR	Ampicillin resistance gene for bacterial selection
pUC ori	pUC origin of replication
5' LTR	5' long terminal repeat
Psi	RNA packaging signal
RRE	Rev response element



Control Selection Table

Sigma's recommended controls for any shRNA experiment are closely aligned with the controls suggested in the *Nature Cell Biology* editorial.⁴

Recommended Control	Objective
Negative Control: Untreated Cells	Untreated cells will provide a reference point for comparing all other samples.
Negative Control: Transfection with empty vector, containing no shRNA insert	MISSION pLKO.1-puro Control Vector, Catalog Number SHC001 The empty vector, pLKO.1-puro, is a useful negative control that will not activate the RNAi pathway because it does not contain an shRNA insert. It will allow for observation of cellular effects of the transfection process and the delivery of the lentiviral vector. Cells transfected with the empty vector provide a useful reference point for comparing specific knockdown.
Negative Control: Transfection with non-targeting shRNA	MISSION Non-Target shRNA Control Vector, Catalog Number SHC002 This non-targeting shRNA vector is a useful negative control that will activate RISC and the RNAi pathway, but does not target any mouse genes. The short-hairpin sequence contains 5 base pair mismatches to any known mouse gene. This allows for examination of the effects of shRNA transfection on gene expression. Cells transfected with the non-target shRNA vector will also provide a useful reference for interpretation of knockdown.
Positive Control: Transfection with positive reporter vector	MISSION TurboGFP™ Control Vector, Catalog Number SHC003 This vector is a useful positive control for measuring transfection efficiency and optimizing shRNA delivery. The TurboGFP Control vector consists of the lentiviral backbone vector, pLKO.1-puro, containing a gene encoding TurboGFP, driven by the CMV promoter. Transfection of this vector provides fast visual confirmation of successful transfection and delivery.
Positive Control: Transfection with shRNA targeting reporter vector	MISSION TurboGFP shRNA Control Vector, Catalog Number SHC004 The TurboGFP shRNA vector consists of the pLKO.1-puro vector, containing shRNA that targets TurboGFP, and can be used as a positive control to quickly visualize knockdown. This TurboGFP shRNA Control Vector has been experimentally shown to reduce GFP expression by 99.6% in HEK 293T cells after 24 hours. Because this vector targets TurboGFP, and it does not target any mouse genes, it can also be used as a negative non-target control in shRNA experiments.

Mouse Cell Type Table

The mouse cell types listed have been successfully infected by pLKO.1-puro based shRNA constructs

Cell lines	Cell Type
NIH 3T3	fibroblast
Primary cells	Cell Type
astrocytes	normal
C3H10T1/2	mesenchymal
ECS	mouse embryonic stem cells
fibroblasts	mouse embryonic fibroblasts
MC3T3-E1	mouse bone marrow derived
molar	mouse embryonic
mesenchymal	mesenchymal

Reviews Indicating the Importance of Each of the Gene Family Sets:

Kinases

1. Gomase, V.S. et al., *Curr. Drug Metab.*, **9**, 255-8 (2008).

Phosphatases

1. Hendriks, W.J. et al., Protein tyrosine phosphatases: functional inferences from mouse models and Murine diseases. *FEBS J.*, **275**, 816-30 (2008).
2. Tremblay, M.L., and Giguère, V., Phosphatases at the heart of FoxO metabolic control. *Cell Metab.*, **7**, 101-3 (2008).
3. Heideker, J. et al., Phosphatases, DNA damage checkpoints and checkpoint deactivation. *Cell Cycle*, **6**, 3058-64 (2007).
4. Sawyer, T.K. et al., Protein phosphorylation and signal transduction modulation: chemistry perspectives for small-molecule drug discovery. *Med. Chem.*, **1**, 293-319 (2005).

Tyrosine Kinases

1. Annerén, C., Tyrosine kinase signaling in embryonic stem cells. *Clin. Sci. (Lond)*, **115**, 43-55 (2008).
2. Comoglio P.M. et al., Drug development of MET inhibitors: targeting oncogene addiction and expedience. *Nat. Rev. Drug Discov.*, **7**, 504-16 (2008).
3. Ren, H. et al., Receptor tyrosine kinases as therapeutic targets in malignant glioma cells. *Rev. Recent Clin. Trials*, **2**, 87-101 (2007).

References

1. Stewart, S.A. et al., Lentivirus-delivered stable gene silencing by RNAi in primary cells. *RNA*, **9**, 493-501 (2003).
2. Zufferey, R. et al., Multiply attenuated lentiviral vector achieves efficient gene delivery *in vivo*. *Nat. Biotechnol.*, **15**, 871-85 (1997).
3. Zufferey, R. et al., Self-inactivating lentivirus vector for safe and efficient *in vivo* gene delivery. *J Virol.*, **72**, 9873-80 (1998).
4. Whither RNAi? *Nature Cell Biology*, **5**, 489-490 (2003).

Label Licenses:**These licenses are relevant for all Mission products:**

Use of this product for Commercial Purposes requires a license from Sigma-Aldrich Corporation. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party, or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration, but excludes not-for-profit core facilities providing services within their own research institutions at cost. Core facilities are invited to join Sigma-Aldrich's RNAi Partnership Program. Details of Sigma-Aldrich's RNAi Partnership Program can be found at www.sigma.com/rpp.

This product is licensed under U.S. Pat. Nos. 5,817,491; 5,591,624; 5,716,832; 6,312,682; 6,669,936; 6,235,522; 6,924,123 and foreign equivalents from Oxford BioMedica (UK) Ltd., Oxford, UK, and is provided for use in academic and commercial *in vitro* and *in vivo* research for elucidating gene function, and for validating potential gene products and pathways for drug discovery and development, but excludes any use of LentiVector® technology for: creating transgenic birds for the purpose of producing useful or valuable proteins in the eggs of such transgenic birds, the delivery of gene therapies, and for commercial production of therapeutic, diagnostic or other commercial products not intended for research use where such products do not consist of or incorporate a lentiviral vector. Information about licenses for commercial uses excluded under this license is available from Oxford BioMedica (UK), Ltd., Medawar Center, Oxford Science Park, Oxford OX4 4GA UK enquiries@oxfordbiomedica.co.uk or BioMedica Inc., 11622 El Camino Real #100, San Diego CA 92130-2049 USA. LentiVector is a registered US and European Community trademark of Oxford BioMedica plc.

This product (based upon the lentikat system) is sub-licensed from Invitrogen Corporation under U.S. Patent Nos. 5,686,279, 5,834,256, 5,858,740; 5,994,136; 6,013,516; 6,051,427, 6,165,782, and 6,218,187 and corresponding patents and applications in other countries for internal research purposes only. Use of this technology for gene therapy applications or bioprocessing other than for nonMURINE research use requires a license from Cell Genesys, Inc. Please contact Cell Genesys, Inc. at 342 Lakeside Drive, Foster City, California 94404. Use of this technology to make or sell products or offer services for consideration in the research market requires a license from Invitrogen Corporation, 1600 Faraday Ave., Carlsbad, CA 92008.

These licenses are relevant for all Mission products but SHP001:

This product is for non-clinical research use only. It is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic, therapeutic or high throughput drug discovery purposes (the screening of more than 10,000 compounds per day) is prohibited. This product is sold under license from Invitrogen Corporation. In order to obtain a license to use this product for these commercial purposes, contact The Regents of the University of California. This product or the use of this product is covered by U.S. Patent No. 5,624,803 owned by The Regents of the University of California.

These licenses are relevant for all Mission products but SHC001, SHC001V, SHC003, SHC003V, SHP001:

Licensed under Carnegie Institution US Patent 6,506,559 and Massachusetts Institute of Technology and for laboratory and commercial research use only.

This product is licensed under agreement with Benitec Australia Ltd. and CSIRO as co-owners of U.S. Pat. No. 6,573,099 and foreign counterparts, for use in research to understand, diagnose, monitor, treat and prevent Murine diseases and disorders, including the use of animals for such research use, except that use of ddRNAi as a therapeutic agent or as a method of disease treatment, prevention, diagnosis or for disease monitoring is excluded. Information regarding licenses to these patents for use of ddRNAi as a therapeutic agent or for other uses excluded under this license is available from Benitec at licensing@benitec.com. Information about licenses for the use of ddRNAi in other fields, is available from CSIRO at pi.csiro.au/RNAi.

This license is relevant for all Mission products but SHC002, SHC002V, SHC003, SHC003V, SHC004, SHC004V, SHP001:

The MISSION shRNA Library of The RNAi Consortium is produced and distributed under license from the Massachusetts Institute of Technology.

This license is relevant for Mission products SHC003, SHC003V, SHXC01:

This product contains a proprietary nucleic acid coding for a proprietary fluorescent protein(s) intended to be used for research purposes only. Any use of the proprietary nucleic acid or fluorescent proteins coding by proprietary nucleic acids other than for research use is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

This Product is covered by US and foreign patent applications or patents and other proprietary intellectual property rights owned by CSHL ("CSHL shRNA IP Rights"), including U.S. Patent Nos. 8,153,776, 8,202,846, 8,383,599, 8,829,264, and EP1546174.

Subject to acceptance and all terms and conditions of this License, sale of the Product to Buyer by Sigma-Aldrich, Co. (acting under its license, an "Authorized Sale") conveys to Buyer only the nonexclusive, nontransferable right (with no right to sublicense) under the shRNA IP Rights to use the Product solely for Customer's internal research purposes, and only at its facility where the Product is delivered by Sigma-Aldrich, Co.

The Product is for research use only and may not be used *in vitro* or *in vivo* for any diagnostic, preventative, therapeutic or vaccine application, or used (directly or indirectly) in humans for any purpose.

Non-Profit Buyers. If Buyer is a Non-Profit Entity, then the following additional restrictions will apply:

Customer obtains no right to use, develop or otherwise exploit the product for any commercial purpose.

Commercial Buyers. If Buyer is a Commercial Entity, then the following additional restrictions will apply:

A Product sale is an Authorized Sale only if Buyer has already entered into a separate written agreement that has been executed by CSHL or Hairpin Technologies, that covers the CSHL shRNA IP Rights, and that is then currently in effect. Any delivery or transfer of Product to Customer outside of an Authorized Sale is void, conveys no implied or express right under this license and Customer will immediately return Product to Sigma-Aldrich for a refund.

"Commercial Entity" means any entity or organization other than a Non-Profit Entity.

"CSHL" means Cold Spring Harbor Laboratory.

"Hairpin Technologies" means Hairpin Technologies, Inc. located at 2200 Smithtown Avenue, Ronkonkoma, NY 11779, www.hairpintechnologies.com.

"Non-Profit Entity" means any college, university or governmental entity (including without limitation, governmental and quasi-governmental institutes and research laboratories), or any non-profit scientific, research or educational organization of the type described in section 501(c)(3) of the Internal Revenue Code or qualified under a state non-profit organization statute.

"Product" means a product (including, without limitation, expression vectors encoding a shRNA, the design, manufacture or use of which (in whole or in part) is the subject of the shRNA IP Rights, and is deemed to include all components, progeny, reproductions, modified versions and other derivatives thereof.

This license is subject to a license from CSHL or Hairpin Technologies, and CSHL and Hairpin Technologies reserves all other rights under its license. For information on licensing rights for Commercial Entities, including use of this product for purposes other than research and trial licenses, please contact Hairpin Technologies, Inc. at info@hairpintechnologies.com or call (631) 881-0844.

MISSION is a registered trademark of Sigma-Aldrich Co. LLC.

TurboGFP is a trademark of Evrogen Co.

PHC,MAM 08/17-1